Epigenetics and complex disease: from etiology to new therapeutics.
暂无分享,去创建一个
[1] M. Bourin,et al. The role of mood stabilisers in the treatment of the depressive facet of bipolar disorders , 2007, Neuroscience & Biobehavioral Reviews.
[2] Mahasti Saghatchian,et al. Molecular targets and cancer therapeutics. , 2004, Drug discovery today.
[3] M. Szyf,et al. Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. , 2007, Biochemical pharmacology.
[4] E. Sausville,et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. , 2007, Blood.
[5] M. Esteller. Cancer epigenomics: DNA methylomes and histone-modification maps , 2007, Nature Reviews Genetics.
[6] Jonathan Pevsner,et al. FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice. , 2007, Human molecular genetics.
[7] J. LaSalle,et al. 15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders. , 2007, Human molecular genetics.
[8] Yi Zhang,et al. Regulation of histone methylation by demethylimination and demethylation , 2007, Nature Reviews Molecular Cell Biology.
[9] D. Waggoner. Mechanisms of disease: epigenesis. , 2007, Seminars in pediatric neurology.
[10] E. Costa,et al. Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder , 2007, Schizophrenia Research.
[11] P. Hajduk,et al. A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature reviews. Drug discovery.
[12] M. Szyf,et al. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. , 2007, Carcinogenesis.
[13] Dong Hoon Kim,et al. Psammaplin A is a natural prodrug that inhibits class I histone deacetylase , 2007, Experimental & Molecular Medicine.
[14] Karl Mechtler,et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. , 2007, Molecular cell.
[15] T. Bijma,et al. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells , 2007, Leukemia.
[16] E. Andres Houseman,et al. Global DNA Methylation Level in Whole Blood as a Biomarker in Head and Neck Squamous Cell Carcinoma , 2007, Cancer Epidemiology Biomarkers & Prevention.
[17] D. Qian,et al. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma , 2007, Molecular Cancer Therapeutics.
[18] Minoru Yoshida,et al. [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.
[19] M. Fang,et al. Dietary polyphenols may affect DNA methylation. , 2007, The Journal of nutrition.
[20] Ronald Breslow,et al. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug , 2007, Nature Biotechnology.
[21] Chunlei Zhang,et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). , 2007, Blood.
[22] Michael Rytting,et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. , 2006, Blood.
[23] Yan Wu,et al. Inhibition of Proliferation of Endometrial Stromal Cells by Trichostatin A, RU486, CDB-2914, N-Acetylcysteine, and ICI 182780 , 2006, Gynecologic and Obstetric Investigation.
[24] Hui Shen,et al. Assessment of genetic linkage and parent-of-origin effects on obesity. , 2006, The Journal of clinical endocrinology and metabolism.
[25] K. Bélanger,et al. Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115. , 2006, Annals of Oncology.
[26] Tae Hoon Kim,et al. Genome-wide analysis of protein-DNA interactions. , 2006, Annual review of genomics and human genetics.
[27] Jessica E. Bolden,et al. Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.
[28] B. Conley,et al. Targeting epigenetic abnormalities with histone deacetylase inhibitors , 2006, Cancer.
[29] P. Houghton,et al. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Zwiller,et al. Fluoxetine and Cocaine Induce the Epigenetic Factors MeCP2 and MBD1 in Adult Rat Brain , 2006, Molecular Pharmacology.
[31] A. Rosemurgy,et al. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] W. Stadler,et al. A phase II study of depsipeptide in refractory metastatic renal cell cancer. , 2006, Clinical genitourinary cancer.
[33] L. Poirier,et al. Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats. , 2006, Carcinogenesis.
[34] Peter Natesan Pushparaj,et al. SHORT INTEFERING RNA (siRNA) AS A NOVEL THERAPEUTIC , 2006, Clinical and Experimental Pharmacology and Physiology.
[35] A. Wagschal,et al. Epigenetic deregulation of imprinting in congenital diseases of aberrant growth. , 2006, BioEssays : news and reviews in molecular, cellular and developmental biology.
[36] E. Richards. Inherited epigenetic variation — revisiting soft inheritance , 2006, Nature Reviews Genetics.
[37] John M Bennett,et al. Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.
[38] Kevin K. Yang,et al. Apoptosis Signal-regulating Kinase 1 Is a Direct Target of E2F1 and Contributes to Histone Deacetylase Inhibitorinduced Apoptosis through Positive Feedback Regulation of E2F1 Apoptotic Activity* , 2006, Journal of Biological Chemistry.
[39] E. Nestler,et al. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action , 2006, Nature Neuroscience.
[40] Arturas Petronis,et al. Complex disease, gender and epigenetics , 2006, Annals of medicine.
[41] Peter A. Jones,et al. Epigenetic therapy of cancer: past, present and future , 2006, Nature Reviews Drug Discovery.
[42] R. Ficner,et al. Crystal structure of a bacterial class 2 histone deacetylase homologue. , 2005, Journal of molecular biology.
[43] C. Steidl,et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia , 2005, Annals of Hematology.
[44] J. Cen,et al. [Mechanism of differentiation and apoptosis in leukemia cells induced by tributyrin]. , 2005, Zhongguo shi yan xue ye xue za zhi.
[45] M. Dokmanovic,et al. Prospects: Histone deacetylase inhibitors , 2005, Journal of cellular biochemistry.
[46] P. Hagerman,et al. Recent advances in fragile X: a model for autism and neurodegeneration , 2005, Current opinion in psychiatry.
[47] T. Spector,et al. Epigenetic differences arise during the lifetime of monozygotic twins. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[48] Emily Bernstein,et al. RNA meets chromatin. , 2005, Genes & development.
[49] Frank Lyko,et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. , 2005, Cancer research.
[50] W. Lam,et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells , 2005, Nature Genetics.
[51] E. Sausville,et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] Alexander V. Lyubimov,et al. Plasma Pharmacokinetics, Oral Bioavailability, and Interspecies Scaling of the DNA Methyltransferase Inhibitor, Zebularine , 2005, Clinical Cancer Research.
[53] Joseph Biederman,et al. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies , 2005, Psychological Medicine.
[54] D. Qian,et al. Epigenetic Modulation of Retinoic Acid Receptor β2 by the Histone Deacetylase Inhibitor MS-275 in Human Renal Cell Carcinoma , 2005, Clinical Cancer Research.
[55] A. Dueñas-González,et al. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes , 2005, BMC Cancer.
[56] D. Reinberg,et al. The key to development: interpreting the histone code? , 2005, Current opinion in genetics & development.
[57] M. Fraga,et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.
[58] E Maestrini,et al. Analysis of IMGSAC autism susceptibility loci: evidence for sex limited and parent of origin specific effects , 2005, Journal of Medical Genetics.
[59] Manel Esteller,et al. DNA methylation and cancer therapy: new developments and expectations , 2005, Current opinion in oncology.
[60] M. Grever,et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. , 2004, Blood.
[61] A. Ardizzoni,et al. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. , 2005, Oncology research.
[62] L. Altucci,et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells , 2005, Nature Medicine.
[63] P. Laird. Cancer epigenetics. , 2005, Human molecular genetics.
[64] S. Grant,et al. The histone deacetylase inhibitor sodium butyrate induces breast cancer cell apoptosis through diverse cytotoxic actions including glutathione depletion and oxidative stress. , 2004, International journal of oncology.
[65] Minoru Yoshida,et al. Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. , 2004, Bioorganic & medicinal chemistry letters.
[66] Michael J Meaney,et al. Epigenetic programming by maternal behavior , 2004, Nature Neuroscience.
[67] Gangning Liang,et al. Preferential response of cancer cells to zebularine. , 2004, Cancer cell.
[68] A. Petronis. The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis , 2004, Biological Psychiatry.
[69] C. Fuke,et al. Age Related Changes in 5‐methylcytosine Content in Human Peripheral Leukocytes and Placentas: an HPLC‐based Study , 2004, Annals of human genetics.
[70] J. Nemunaitis,et al. Phase I Study of Oral CI-994 in Combination with Carboplatin and Paclitaxel in the Treatment of Patients with Advanced Solid Tumors , 2004, Cancer investigation.
[71] K. Camphausen,et al. Enhanced Radiation-Induced Cell Killing and Prolongation of γH2AX Foci Expression by the Histone Deacetylase Inhibitor MS-275 , 2004, Cancer Research.
[72] A. Wozniak,et al. Chronic Oral Administration of CI-994: A Phase I Study , 2004, Investigational New Drugs.
[73] Jorge A. Almenara,et al. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. , 2003, Molecular cancer therapeutics.
[74] P. Atadja,et al. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). , 2003, Journal of medicinal chemistry.
[75] Robert A. Waterland,et al. Transposable Elements: Targets for Early Nutritional Effects on Epigenetic Gene Regulation , 2003, Molecular and Cellular Biology.
[76] J. Bennett,et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. , 2003, Molecular vision.
[77] M. D'Esposito,et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia , 2003, The Lancet.
[78] E. Eisenhauer,et al. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[79] Carl O. Pabo,et al. Drug discovery with engineered zinc-finger proteins , 2003, Nature Reviews Drug Discovery.
[80] R. Jaenisch,et al. Chromosomal Instability and Tumors Promoted by DNA Hypomethylation , 2003, Science.
[81] R. Strausberg,et al. From Knowing to Controlling: A Path from Genomics to Drugs Using Small Molecule Probes , 2003, Science.
[82] Rosanna Weksberg,et al. Beckwith-Wiedemann syndrome demonstrates a role for epigenetic control of normal development. , 2003, Human molecular genetics.
[83] P. Laird. Early detection: The power and the promise of DNA methylation markers , 2003, Nature Reviews Cancer.
[84] Wei Ye,et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. , 2003, Journal of the National Cancer Institute.
[85] Max Costa,et al. Epigenetics and the Environment , 2003, Annals of the New York Academy of Sciences.
[86] Kuang-Hung Cheng,et al. Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code , 2003, Annals of the New York Academy of Sciences.
[87] A. Bird,et al. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals , 2003, Nature Genetics.
[88] F. McMahon,et al. Additional, physically ordered markers increase linkage signal for bipolar disorder on chromosome 18q22 , 2003, Biological Psychiatry.
[89] A. Paterson,et al. Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance? , 2003, Schizophrenia bulletin.
[90] H. Hoogsteden,et al. Asthma remission: does it exist? , 2003, Current opinion in pulmonary medicine.
[91] C. Sung,et al. Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. , 2002, Cancer letters.
[92] Lei Zhou,et al. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. , 2002, Journal of molecular biology.
[93] M. Ehrlich,et al. DNA methylation in cancer: too much, but also too little , 2002, Oncogene.
[94] D. Fallin,et al. Evidence for parent of origin effect in late-onset Alzheimer disease. , 2002, American journal of medical genetics.
[95] G. Wolff,et al. Maternal methyl supplements in mice affect epigenetic variation and DNA methylation of offspring. , 2002, The Journal of nutrition.
[96] S. Baylin,et al. Altered methylation patterns in cancer cell genomes: cause or consequence? , 2002, Cancer cell.
[97] Albert Jeltsch,et al. Beyond Watson and Crick: DNA Methylation and Molecular Enzymology of DNA Methyltransferases , 2002, Chembiochem : a European journal of chemical biology.
[98] S. Bates,et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[99] W. Wilson,et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. , 2001, Blood.
[100] D. Bernhard,et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[101] A. Petronis,et al. Human morbid genetics revisited: relevance of epigenetics. , 2001, Trends in genetics : TIG.
[102] M. Yoshida,et al. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[103] S. Biade,et al. Chemical agents that promote chromatin compaction radiosensitize tumour cells , 2001, International journal of radiation biology.
[104] F. Demenais,et al. Detection of Parent‐of‐Origin Effects for Atopy by Model‐Free and Model‐Based Linkage Analyses , 2001, Genetic epidemiology.
[105] H. W. Lee,et al. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. , 2000, Cancer research.
[106] J. Herman,et al. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. , 2000, Trends in genetics : TIG.
[107] M. Lübbert,et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[108] P. Marks,et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.
[109] H. Ostrer. Sex-based differences in gene transmission and gene expression , 1999, Lupus.
[110] Peter A. Jones,et al. Cancer-epigenetics comes of age , 1999, Nature Genetics.
[111] R. Kodell,et al. Maternal epigenetics and methyl supplements affect agouti gene expression in Avy/a mice , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[112] A. Riggs,et al. Methylation dynamics, epigenetic fidelity and X chromosome structure. , 1998, Novartis Foundation symposium.
[113] M. Seeman. Psychopathology in women and men: focus on female hormones. , 1997, The American journal of psychiatry.
[114] N. Mori,et al. Anticipation and Imprinting in Schizophrenia , 1997, Biological Psychiatry.
[115] S Henikoff,et al. Exploring and explaining epigenetic effects. , 1997, Trends in genetics : TIG.
[116] D M Schmatz,et al. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[117] R A Rifkind,et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[118] D. Barlow,et al. Gametic Imprinting in Mammals , 1995, Science.
[119] M. Yoshida,et al. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. , 1993, The Journal of biological chemistry.
[120] D. Reiss,et al. Genetics and psychiatry: an unheralded window on the environment. , 1991, American Journal of Psychiatry.
[121] M. Azim Surani,et al. Epigenetic control of transgene expression and imprinting by genotype-specific modifiers , 1990, Cell.
[122] J. Hall,et al. Genomic imprinting: review and relevance to human diseases. , 1990, American journal of human genetics.
[123] M. Yoshida,et al. Effects of trichostatins on differentiation of murine erythroleukemia cells. , 1987, Cancer research.
[124] Peter A. Jones,et al. Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.